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■ Abstract
Chronic urticaria has an important impact upon patient quality of life, and no treatment has yet been developed capable of effectively 
controlling the disease. The most recent guidelines recommend the use of non-sedating antihistamines at high doses as second-step 
therapy before resorting to other treatments. The present review examines the studies published to date on the use of H1 antihistamines 
at doses higher than those indicated as therapeutic doses in chronic urticaria. Most of the studies report no significant differences among 
the studied doses – only a tendency towards increased response on elevating the dose.There are no clinically well designed, randomized 
double-blind trials comparing efficacy between therapeutic doses and doses higher than those indicated in the corresponding Summary 
of Product Characteristics. Likewise, there are insufficient data to conduct a meta-analysis and thus classify the degree of evidence of the 
few available studies, which moreover present contradictory results. At present, the prescription of high-dose H1 antihistamines is based 
only on experts opinion. However, considering the high safety profile of these drugs, it would be a good option to evaluate their efficacy 
at high doses, before moving on to other therapeutic steps. 
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■ Resumen
La urticaria crónica es una enfermedad que afecta de una forma importante a la calidad de vida, para la que todavía no contamos con 
un tratamiento efi caz capaz de controlarla. Las guías más recientes recomiendan emplear antihistamínicos no sedantes a dosis elevadas 
como segundo escalón terapéutico antes de emplear otros tratamientos.
En esta revisión repasamos los estudios publicados hasta ahora sobre el empleo de antihistamínicos-H1 a dosis superiores a las indicadas 
como terapéuticas en urticaria crónica. La mayoría de estudios no encuentran diferencias signifi cativas entre las dosis estudiadas, única-
mente una tendencia a incrementar la respuesta al incrementar la dosis. No existen estudios clínicamente bien diseñados y distribuidos 
aleatoriamente a doble ciego que comparen la efi cacia entre dosis terapéuticas con dosis superiores a la indicada en la fi cha técnica. 
Tampoco hay datos sufi cientes para realizar un meta-análisis y poder clasifi car el grado de evidencia de los escasos estudios –con resul-
tados contradictorios- de que se dispone. Por el momento, la prescripción de antihistamínicos H1 a dosis elevadas se basa únicamente 
en opinión de los expertos, si bien, por el elevado perfi l de seguridad de estos fármacos, será una buena opción, antes de pasar a otros 
escalones terapéuticos, ensayar la efi cacia de dosis altas de antihistamínicos.
Palabras clave: Urticaria crónica. Antihistamínicos. Tratamiento urticaria crónica.
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Introduction 
H1 antihistamines [1] are inverse agonists that bind to 
H1 receptors, stabilizing the latter in the inactive conformation 
and therefore interfering with histamine action upon these 
receptors. Antihistamines are divided into fi rst- and second-
generation drugs. The former have been in use since the 1940s 
and 1950s [2], and are derivatives of muscarinic antagonists, 
tranquillizers, antipsychotics and antihypertensive agents. 
The fi rst generation of antihistamine drugs is characterized 
by low selectivity for the H1 receptors – as a result of which 
they induce antimuscarinic, anti-alpha-adrenergic and anti-
serotoninergic effects. Their main inconvenience is the fact 
that they cross the blood-brain barrier. The so-called second-
generation antihistamines appeared in the 1980s [3,4], and 
are characterized by minimum sedation, due to their limited 
ability to cross the blood-brain barrier, and their high affi nity 
and selectivity for histamine H1 receptors. 
Chronic urticaria is characterized by episodes of pruriginous 
erythematous-wheal lesions. By defi nition, the wheals last less 
than 24 hours, and manifest for at least 6 weeks, during which 
the episodes occur daily or are present more than twice a week. 
In 50% of all cases urticaria is associated to angioedema [5]. 
The calculated prevalence [6] in the Spanish population is 
0.65 (95%CI: 0.4-0.8). In 80% of the cases an etiological diag-
nosis is not established – these presentations being described 
as idiopathic chronic urticaria. Of the remaining 20%, physical 
urticarias represent 15% and other types of urticaria 5%. 
A Spanish national study [7] on the epidemiological, clini-
cal and socioeconomic factors of allergic diseases showed this 
disorder represents a strong impact upon patient perceived qua-
lity of life, causing many visits to the emergency department 
and leading to important sick leave from work or diminished 
school performance. In this context, in relation to the “phy-
sical” quality of life subscale of the SF-12 questionnaire, the 
mean score of the patients with urticaria / angioedema is in 
percentile 25 of the quality of life score distribution of the 
Spanish general population, while the mean “mental” quality 
of life score is under percentile 20. 
Despite the morbidity and impact upon patient quality of 
life [8,9], no treatment to date has been able to fully control 
the disease. The latest consensus documents and guidelines 
[10,11] recommend the start of treatment with antihistamines 
at therapeutic doses, though in the event of insuffi cient res-
ponse, they advise a progressive two-, three- or even four-fold 
increase in the dosage. If the prescription of supratherapeutic 
doses likewise fails to elicit the desired response, short-course 
corticosteroids are recommended, and if this does not prove 
effective, then the only drug to have demonstrated effi cacy in 
one-third of the cases examined in the context of randomized 
and placebo-controlled trials is cyclosporine [12,13]. On the 
other hand, very promising results have been published for 
omalizumab [14-16], despite its high cost [17].
High Doses in Physical Urticarias 
All studies published to date refl ect a greater response with 
supratherapeutic antihistamine doses than with the usual doses. 
Mention should be made to the observations of Siebenhaar 
et al. [18], who in a randomized, double-blind, three-way 
cross-over prospective study showed that the administration 
of 5 and 20 mg of desloratadine signifi cantly increased the 
tolerance threshold of the cold exposure test. This study found 
no increase in drowsiness or adverse events with the 20 mg 
dose of desloratadine. 
Previously, in patients with cholinergic urticaria, similar 
results had been obtained for cetirizine at supratherapeutic 
doses [19]. 
However, all these studies are referred to physical urticaria, 
and the mediator in such cases is histamine and so, it is logical 
to expect better responses with higher doses of antihistamines. 
Chronic Urticaria 
In the case of chronic urticaria, the treatment guidelines 
have agreed to include [11] the possibility of increasing an-
tihistamine doses up to four times with respect to the doses 
recommended in the Summary of Product Characteristics, if 
good control is not achieved with the therapeutic doses. 
Nevertheless, this recommendation is based on experts 
opinion, and clinical consensus has not yet been reached, since 
published results from several studies are contradictory . The 
fi rst two studies refer to the safety and effi cacy of fexofenadine. 
The fi rst trial, double-blind and group-controlled, was publis-
hed by Kaplan et al. in 1999 [20], and involved 439 patients 
with chronic urticaria treated with fexofenadine. The authors 
observed no increase in response with progressively rising drug 
doses, for although there were differences between the three 
highest doses and the lowest dose, no signifi cant differences 
were recorded among these highest doses. They only found that 
the three highest doses were superior to the 20 mg dose. The 
second study, comprising four weeks of treatment, involved 
a randomized, double-blind and placebo-controlled design, 
with 418 patients. Improvement in all parameters was recorded 
with the doses of 20, 60, 120 and 240 mg of fexofenadine. 
There were differences between the two highest doses versus 
the 20 mg dose, but not between the rest of the drug doses. 
Nevertheless, there was a clear tendency towards symptoms 
improvement when dosage was increased [21]. 
A third study has been published by Asero et al. [22], 
involving 22 patients with refractory chronic urticaria failing 
to respond to therapeutic doses of antihistamines. The patients 
were administered with rising doses of cetirizine (from 10 to 
30 mg), with a responder in only one of the 22 patients. 
Bilastine has been studied at different doses in a dose-
fi nding phase II study involving 222 patients with chronic 
urticaria [23]. This study compared 10, 20 and 30 mg of bilas-
tine, in four parallel groups, versus a placebo control, basing 
effi cacy on the number of wheals and itching. Statistically 
signifi cant differences were found for all three doses versus 
placebo, with no differences between doses, though the effect 
was up-dosing dependent (see Figure). Subsequently, identical 
results were obtained in the phase III studies. [24]. 
Lastly, a more recent randomized, double-blind cross-
over study [25] has compared the effi cacy of levocetirizine 
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Figure. Dose-fi nding study (phase II). Evolution of total symptoms score in patients with chronic urticaria 
treated with bilastine 10, 20 and 30 mg/day.
*** p<0.001 vs placebo.
and desloratadine in 80 patients with 
diffi cult-to-treat chronic urticaria, ad-
ministering increasing doses of 5, 10, 
15 and 20 mg of both antihistamines 
if there was poor symptoms control. 
This study, in contrast to the previous 
trials, appears to demonstrate that the 
response is significantly greater to 
the increase  of antihistamine dose. It 
was found that 13 patients responded 
to a dose of 5 mg (9 in the levocetiri-
zine group and 4 in the desloratadine 
group), 15 more responded to 10 mg 
(8 and 7 in the other groups, respecti-
vely), and 6 more to a dose of 20 mg 
(5 and 1, respectively). However, this 
still left 18 patients in the levocetiri-
zine group and 25 in the desloratadine 
group that failed to respond to the 
highest antihistamine dose (20 mg). 
Levocetirizine showed signifi cantly 
better behaviour than desloratadine 
at all doses, also in relation to patient 
quality of life. This study offered a 
secondary fi nding of great interest, patients did not experience 
an increase in drowsiness with the up-dosing, and drowsiness 
even improved in the case of levocetirizine. This appears to 
support the hypothesis that drowsiness in patients with urticaria 
is due to interferences with sleep caused by the disease rather 
than by the use of antihistamines. Furthermore, these results 
show that with second-generation antihistamines it is possible 
to establish a good itch and nighttime rest control, being a 
better option than associating a fi rst-generation antihistamine 
in a bedtime dose, which in effect would increase drowsiness, 
particularly taking into account the references of the recent 
guidelines on the use of fi rst-generation antihistamines [26]. 
Another study has been published, though in this case it is 
an analysis of data accumulated from two randomized trials 
versus placebo, administering rupatadine [27]. The study 
concluded that both, the 10 mg and the 20 mg dose, elicit a 
signifi cantly superior response versus placebo, though with the 
20 mg dose a higher number of patients obtained a response 
of 75% improvement. When examining the studies separately, 
the fi rst of them [28], a phase II trial comparing doses of 5, 
10 and 20 mg, revealed no differences between placebo and 
the 5 mg dose. No differences were recorded in terms of the 
number of wheals or in the symptoms scores between the 10 
and 20 mg doses, though a clear dose-response effect was 
observed in favour of the 20 mg dose. The second trial [29] in 
turn compared the 10 and 20 mg doses, recording no signifi cant 
differences between them in any of the studied parameters: 
itching, number of wheals or symptoms scores. 
The results are summarized in the Table 1. 
The described fi ndings indicate that there is a predomi-
nance of studies that record no signifi cant differences between 
doses, though all of them report a certain dose-response effect 
in relation to both itching and the number of wheals, as the 
drug dose is increased. The discrepancy among studies may 
be due to the antihistamine employed. Due caution is required, 
however, since there are two studies that include 22 and 80 
patients, respectively, versus 857 patients in the studies with 
fexofenadine, or 222 patients with bilastine. 
In sum, a number of studies suggest the possibility of 
using supratherapeutic doses of antihistamines for contro-
lling chronic urticaria, as agreed by the experts. There are no 
randomized, double-blind trials comparing effi cacy between 
therapeutic doses and doses higher than those indicated in the 
corresponding Summary of Product Characteristics. Likewise, 
there are insuffi cient data to conduct a meta-analysis and thus 
classify the degree of evidence of the few available studies, 
which moreover present contradictory results. 
On the other hand, it must be considered that the key 
factor for antihistaminic activity in treating skin diseases is 
its distribution at cutaneous level. In this sense, Simons [30] 
published a very illustrative study comparing three antihis-
tamines (fexofenadine, loratadine and chlorpheniramine), 
administered at therapeutic doses on a randomized basis, in 
parallel and with a placebo control group. The study showed 
the cutaneous concentrations of the three antihistamines diffe-
red signifi cantly; that is, the second-generation drugs reached 
higher levels than the fi rst-generation compound. Likewise, 
fexofenadine was the most potent antihistamine, reaching 
higher skin concentrations and with faster action. In the case 
of the fi rst-generation antihistamine (chlorpheniramine), no 
detectable skin concentrations were recorded, and its potency 
in inhibiting histamine-induced wheals was signifi cantly lower. 
This study evaluated each antihistamine at therapeutic doses, 
though it would be very interesting to assess the cutaneous 
distribution in the same way as in the mentioned study, but 
administering different antihistamine doses, and comparing 
histamine-induced wheal inhibiting potency in parallel. 
It is also important to mention that in daily clinical prac-
tice it is not common to increase the antihistamine dosage 
for treating patients with chronic urticaria. This was refl ected 
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Table 1. Comparison of the included studies
 Study Design Duration Antihistamine No. patients Dose (mg) Difference with
       high doses
 
Finn AF20 Placebo-controlled, 
  randomized, double-blind 4 weeks Fexofenadine 439 20, 60, 120, 240 No
Nelson HS21 Placebo-controlled, 
  randomized, double-blind 4 weeks Fexofenadine 418 20, 60, 120, 240 No
Asero R22 Open, observational 2 weeks Levocetirizine 22 10, 30 No
Audicana M24 Phase II, dose-response, 
  randomized, double-blind, 
  placebo-controlled, parallel 4 weeks Bilastine 222 10, 20, 30 No
Dubertret L29 Phase II, dose-response,      Yes, between 5
  randomized, double-blind,      and 10/20, not 
  placebo-controlled, parallel 4 weeks Rupatadine 277 5, 10, 20 between 10
       and 20  
Gimenez- Randomized, double-blind, 
Arnau AM28 placebo-controlled, parallel 4 weeks Rupatadine 283 10, 20 No
Staevska M26 Double blind,   Levocetirizine and   Improvement in
  randomized, parallel  Desloratadine 88 5, 10, 20 2/3 of the
       patients
in a study of 695 patients [3] on the application of treatment 
guidelines and the way of treating chronic urticaria, based on 
questionnaires cumplimented by allergologists and dermatolo-
gists. For none of the considered antihistamines did this study 
fi nd a mean or median dose above the dosage recommended 
in the corresponding Summary of Product Characteristics. 
The observed tendency was to add a second drug instead of 
increasing the antihistamine dose. 
Finally, it must be remembered that other mediators, 
cytokines and chemokines, intervene in chronic urticaria, apart 
from histamine. In this sense, it has been shown that when 
incubating healthy mast cells and basophils with sera from 
patients with chronic urticaria, the cells produced IL-4 and 
leukotrienes [32]. These mediators could explain the perivascular 
infi ltrates that characterize chronic urticaria [33], since these 
cytokines and chemokines would attract the mentioned cells 
towards the skin. The described infi ltrate is clearly differentiated 
from the histopathological lesion corresponding to acute urticaria 
or physical urticaria; it therefore would be logical for chronic 
urticaria not to respond only to antihistamines. 
In conclusion, it may be stated that while an antihistamine 
dose increment logically may be expected to elicit symptoms 
control in histamine - mediated physical urticarias, this point is 
not clear in the case of chronic urticaria. Studies are therefore 
needed to clarify this issue. Until then, the above postulate 
remains a matter of expert opinion only, though the very 
good safety profi le of some second-generation antihistamines 
could allow the use of doses higher than those specifi ed in the 
Summary of Product Characteristics. Furthermore, the side 
effects of the alternative treatments are comparatively more 
negative. Therefore, before resorting to other therapeutic steps, 
it always seems to be a good option to test the effi cacy of the 
second-generation antihistamines at supratherapeutic doses, 
even if on an empirical basis [34]. 
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